Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BGI Genomics Co. Ltd.

www.bgi.com

Latest From BGI Genomics Co. Ltd.

Trade War‘s Next Frontier? China Genetic Material Regs Could Set Back Biopharma Research

A new rule regulating the collecting, storing and transporting of genetic samples and materials in China sets new limits on international companies looking to conduct work with biologic and gene therapies in potentially the most promising market for these emerging technologies.

China Regulation

Pacts In Medtech: Glaukos To Distribute Saten's MicroShunt; Acell Signs Distribution Deals

Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.

Pacts in Medtech Deals

Asia's Nasdaq? Hong Kong‘s Quest To Be IPO Power House Has Blessings And Curses

Hundreds of executives showed up at an inaugural biotech summit organized by the Hong Kong Stock Exchange, setting the stage for a showdown between the territory and the most popular destination for biotech IPOs, Nasdaq in the US. Despite recent rule changes to allow pre-revenue biotechs to gain a listing more easily, executives still see hurdles that are associated with Hong Kong's close proximity to the very market it is trying to allure, mainland China.

Financing Hong Kong

China In 2018: Watch Out For AI, CAR-T And Biotech Unicorns

Armed with massive amounts of data, China is poised to make a dent in big data-driven innovation and artificial intelligence applications including smart health. A policy push to encourage the development of novel drugs also means there may be more biotech unicorns and innovative therapies to attract investment inflows.

Platform Technologies ImmunoOncology
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
  • Research, Analytical Equipment & Supplies
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • BGI
  • BGI-Shenzhen
  • Beijing Genomics Institute
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • China
  • Parent & Subsidiaries
  • BGI Genomics Co. Ltd.
  • Senior Management
  • Jun Wang, PhD, CEO
    Xun Xu, VP, R&D
  • Contact Info
  • BGI Genomics Co. Ltd.
    Phone: 755 25273620
    BGI Park, No.21 Hongan 3rd St.
    Bldg. #7
    Shenzhen, 518083
    China
UsernamePublicRestriction

Register